- 积分
- 4277
- 威望
- 4277
- 包包
- 7646
|
肿瘤免疫的概念起源于本世纪初。1909年Ehrlich首先提出,免疫系统不仅负责防御微生物侵犯,而且能从肌体内清除改变了的宿主成分。此后人们认识到癌细胞是改变了的宿主成分。本世纪中期,Foley证实,纯系小鼠诱发的肿瘤能在同系小鼠之间移植,如在肿瘤的生长过程中将移植瘤完全切除,小鼠会对再次接种的肿瘤产生抵抗能力,再次接种的肿瘤或者不再生长,或者长到一定的大小便自行消退。这种抗性有专一性,因为它对再次接种来源于同系动物的另一肿瘤没有抵抗能力。实验说明,肿瘤确能被宿主视为"非己"而产生特异的免疫排斥反应。这使人们相信机体存在着抗肿瘤免疫机制。六十年代经Thomas、Burnet和Good等人将该观点系统化,提出了免疫监视学说。免疫监视学说的中心思想是:免疫系统具有一个十分完备的监视功能,能精确地分?quot;自己"和"非己"的成分;它不仅能清除外界侵入的各种微生物,排斥同种异体移植物,而且还能消灭机体内突变的细胞,防止肿瘤的生长,保护机体的健康。每当免疫监视功能由于这种或那种原因被削弱时,便为肿瘤的发生提供了有利条件;如果机体不具备免疫监视功能,人类的肿瘤发病率会大大提高。 临床也得到了一些支持的证据。但是目前仍然存在争论。& [' Y3 o- X$ a
) w; W M" {8 f d
1)Burnet FM.
) Q k9 e# ?; u2 L1 `' {/ Y2 KThe concept of immunological surveillance.' H$ _ r% r6 Z; G
Prog Exp Tumor Res. 1970;13:1-27. Review. .
; {) j2 p! L! DPMID: 4921480 [PubMed - indexed for MEDLINE] ( l" @, C/ D* @9 Y2 ]2 f
( a8 n& e! s H
2)Burnet FM. Related Articles, Links ; Q2 W+ ^! z8 W) p' Q
Immunological surveillance in neoplasia.
8 ~9 n% x( s# y2 V% \( J3 I% x1 zTransplant Rev. 1971;7:3-25. , a! H! C4 N4 S# |* h& [1 a. I
PMID: 5146537 [PubMed - indexed for MEDLINE] 8 z( v6 L: `2 j* G2 a9 _7 e# R" N7 m
9 `3 Z- a. U) _" n6 {2 S8 P目前关于免疫监视学说的进展和改进( [( y% H7 L2 O" Z2 D1 m
w) E7 {6 F. u, _, a1)Klein G, Klein E. 1 B* D! `' u Z; L
Surveillance against tumors--is it mainly immunological?1 z! e! ?0 b) i- g# H
Immunol Lett. 2005 Aug 15;100(1):29-33. Review.
. r/ {( F- Q/ x; ePMID: 16129497 [PubMed - indexed for MEDLINE]
/ N b5 U. i; ~4 P0 h7 w D0 K1 o/ Z2 i1 n( |/ k7 x
2)Zitvogel L, Tesniere A, Kroemer G.
. D/ [3 K" [ ~* O9 oCancer despite immunosurveillance: immunoselection and immunosubversion.
' j$ Q& P& B9 w! k. aNat Rev Immunol. 2006 Oct;6(10):715-27. Epub 2006 Sep 15. Review. , H, e& t" Z. n: g- E
PMID: 16977338 [PubMed - indexed for MEDLINE] 3 U2 E/ \' h: Z3 k6 k/ M( m
; C; o0 {9 X, Q0 K: u: j3)Smyth MJ, Dunn GP, Schreiber RD.
2 Q+ c0 t* ^) J! g9 zCancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.$ h* x- h9 m. U. i% W8 T3 C2 K: C+ B
Adv Immunol. 2006;90:1-50.
$ M8 d) J* ]8 T$ K- e1 V6 wPMID: 16730260 [PubMed - in process]
1 o7 E0 b! J7 R3 W5 q
. Z/ {% i( h; r1 d: j4)Ichim CV. ' k( a6 S4 `' [/ x
Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy.
- f# I% k! J3 m! XJ Transl Med. 2005 Feb 8;3(1):8. 8 b6 H7 h7 j7 i6 Y8 a( s
PMID: 15698481 [PubMed - as supplied by publisher]
% h: d/ y9 s* L& j+ [
% J; @# i$ ]" ~7 Q# Y |5)Dunn GP, Old LJ, Schreiber RD.
* M7 U4 R/ u2 i+ t. ?The immunobiology of cancer immunosurveillance and immunoediting.
7 D" I# m5 X. g( D. J/ cImmunity. 2004 Aug;21(2):137-48. Review.
, y1 m; L" r4 r; U$ ePMID: 15308095 [PubMed - indexed for MEDLINE] 6 s- C9 J0 f: d" j, x
2 ?4 c2 D- A; d) |: C7 d
6) Qin Z, Blankenstein T.
% k0 v4 L3 n: F# S" vA cancer immunosurveillance controversy.2 ?2 h* L% b& y0 }6 q; ?
Nat Immunol. 2004 Jan;5(1):3-4; author reply 4-5. No abstract available.
7 [! F" J' N w+ Q9 z& d* D: YPMID: 14699396 [PubMed - indexed for MEDLINE]
" N+ Y+ V/ S! \: p4 T
: }& J6 s0 y: _7 r( Y9 o6 I7) Boon T, van Baren N. 6 Y' m, q6 b* S; g' O3 U
Immunosurveillance against cancer and immunotherapy--synergy or antagonism?
' L3 f. y' |; D0 p- ?9 GN Engl J Med. 2003 Jan 16;348(3):252-4. 8 w: T0 G5 t+ M) k+ X' ^/ i
PMID: 12529468 [PubMed - indexed for MEDLINE] 3 g1 {' M9 x: [( `
: @& [- y' S7 B+ A' {: E, j
8: Ochsenbein AF. + N2 l* @0 y( F9 I
Principles of tumor immunosurveillance and implications for immunotherapy.
* O" B8 Q4 K& v0 ECancer Gene Ther. 2002 Dec;9(12):1043-55. Review. 5 ^# n+ T. s' v( j* N; O* @
PMID: 12522443 [PubMed - indexed for MEDLINE] . \. [+ [+ ~+ o
4 T# h& S$ T5 T3 @/ Y
9: Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD.
2 A( V& i/ |& H9 BCancer immunoediting: from immunosurveillance to tumor escape.1 l) M- Z- l5 X$ t! A
Nat Immunol. 2002 Nov;3(11):991-8. Review.
6 `$ d" D# l! p& T; E1 x# ~; xPMID: 12407406 [PubMed - indexed for MEDLINE] ' ^$ I4 O$ x" Z
2 L5 T) f/ U5 \/ J! |
10)Lanier LL. P: v% S' g. F$ U3 T: X' b, y
A renaissance for the tumor immunosurveillance hypothesis.7 S; @, u2 ]) I! p. x% q2 X8 G
Nat Med. 2001 Nov;7(11):1178-80. / M9 u5 e6 u1 S5 Z
PMID: 11689875 [PubMed - indexed for MEDLINE]
/ X0 ?$ Y0 R8 x0 `+ j" G
7 H8 M& q9 ]9 w# o-------------------------------------------------------------------------
9 a2 y3 f) ^6 u Y2 {/ _* e) r' O$ J著名的肿瘤免疫学奠基人之一Richmond T. Prehn首先发现肿瘤特异性抗原,在1970年左右提出肿瘤免疫刺激学说,与诺贝尔奖获得者Bernet的免疫监视学说相反。' v7 h% N/ V1 W% s# w$ x
! I b: \2 L5 V% n. j3 v1)Prehn RT, Lappe MA.
5 m: h% x1 }+ B: ^6 aAn immunostimulation theory of tumor development.9 n- S) P* p3 D9 ?1 h' N# y
Transplant Rev. 1971;7:26-54. Review. 5 @0 r- ^& Q5 ~
PMID: 4947774 [PubMed - indexed for MEDLINE]
8 Y4 f( ~7 u. t1 n2) Prehn RT. & h8 [- W/ { w
Immunosurveillance, regeneration and oncogenesis.
2 F( s9 p! a2 r1 G. O' j) P8 h% sProg Exp Tumor Res. 1971;14:1-24. Review. . 6 G# p& ?, C4 g5 O
PMID: 4944395 [PubMed - indexed for MEDLINE]
/ c" @ B( Q3 z: H8 H3)Prehn RT, Prehn LM.
( R. D) x6 I0 S( k7 PThe autoimmune nature of cancer.
9 S6 d# k) J( Y9 j* i+ E4 TCancer Res. 1987 Feb 15;47(4):927-32. Review.
$ o5 X c& C2 O$ BPMID: 3542202 [PubMed - indexed for MEDLINE] 7 M+ y: H; ?( I f4 q) Y
4)Prehn RT, Prehn LM. . n1 `, \+ l# N9 n2 L/ B; T
Immunostimulation of cancer versus immunosurveillance.
% [/ z# \9 y. {Medicina (B Aires). 1996;56 Suppl 1:65-73. Review. & t$ D* F |/ } [. z
PMID: 9224976 [PubMed - indexed for MEDLINE]
& T; `8 P/ c6 G4 w+ _9 }) ?% a5) Prehn RT.
$ M! h" J) r9 q7 ]* V7 H" z+ LStimulatory effects of immune reactions upon the growths of untransplanted tumors.2 e" H& z* Q: ?
Cancer Res. 1994 Feb 15;54(4):908-14. Review. `7 v- S1 O9 [
PMID: 8313380 [PubMed - indexed for MEDLINE] : k. {) z; n- o5 j: r h# X+ h7 P
6)Prehn RT. 0 b5 R4 A. i. x: ~' h( n6 Q
An adaptive immune reaction may be necessary for cancer development.% F" q- W# a& l) }! r* z
Theor Biol Med Model. 2006 Feb 3;3(1):6 [Epub ahead of print] " A$ r8 h" W' `2 S# W+ p+ Q
PMID: 16457723 [PubMed - as supplied by publisher] |
|